Patent US5225196A successfully refreshed from Google Patents.
US5225196A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bioadhesive compositions and methods of treatment therewith
Assignee: Juniper Pharmaceuticals Inc
•
Filing: 1991-01-07
•
Granted: 1993-07-06
•
Expires: 2011-01-07
Abstract
Abstract A controlled release treatment composition method of use are disclosed. The composition includes a bioadhesive and an effective amount of a treating agent. The bioadhesive is a water-swellable, but water-insoluble, fibrous, cross-linked carboxy-functional polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5 percent cross-linking agent substantially free from polyalkenyl polyether.
Inventors
- 👤 Joseph R. Robinson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 09:41
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5026; A61K9/70; A61K9/7007; A61K9/7023
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
134 words
A controlled release ophthalmic treatment composition comprising a bioadhesive and an effective amount of an ophthalmic treating agent, said bioadhesive comprising a water-swellable, but water-insoluble, particulate cross-linked carboxyl-functional polymer said polymer derived from monomers selected from the group consisting of acrylic acid, methacrylic acid, fumaric acid, maleic acid, maleic anhydride, itaconic acid, crotonic acid and mixtures thereof having particles sized so that visual impairment is substantially minimized when said composition is contacted with a mucous membrane of the eye, said polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) a cross-linked agent substantially free from polyalkenyl polyether said agent selected from the group consisting of divinyl benzend, N,N-dialkylacrylamide, 3,4-dihydroxy-1,5-hexadiene and 2,5-dimethyl-1,5-hexadiene, said agent being from about 0.05 to 2.0 weight.
Claim 2
Dependent Claim
134 words
A controlled release ophthalmic treatment composition comprising a bioadhesive and an effective amount of an ophthalmic treating agent, said bioadhesive comprising a water-swellable, but water-insoluble, particulate cross-linked carboxyl-functional polymer said polymer derived from monomers selected from the group consisting of acrylic acid, methacrylic acid, fumaric acid, maleic acid, maleic anhydride, itaconic acid, crotonic acid and mixtures thereof having particles sized so that visual impairment is substantially minimized when said composition is contacted with a mucous membrane of the eye, said polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) a cross-linked agent substantially free from polyalkenyl polyether said agent selected from the group consisting of divinyl benzend, N,N-dialkylacrylamide, 3,4-dihydroxy-1,5-hexadiene and 2,5-dimethyl-1,5-hexadiene, said agent being from about 0.05 to 2.0 weight.
Claim 3
Dependent Claim
23 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein said bioadhesive and said treating agent are intimately admixed substantially uniform.
Claim 4
Dependent Claim
28 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein at least about 90 percent of said polymer repeating units contain at least one carboxyl functionality.
Claim 5
Dependent Claim
28 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein at least about 95 percent of said polymer repeating units contain at least one carboxyl funtionality.
Claim 6
Dependent Claim
27 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein said polymer contains about 0.01 to about 2 percent by weight of polymerized cross-linking agent.
Claim 7
Dependent Claim
21 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein said carboxyl functionality is provided by polymerized acrylic acid.
Claim 8
Dependent Claim
48 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein at least about 95 percent of said polymer repeating units contain at least one carboxyl functionality provided by acrylic acid, and said polymer contains about 0.01 to about 2 percent by weight of polymerized cross-linking agent.
Claim 9
Dependent Claim
17 words
A controlled release ophthalmic treatment composition as recited in claim 7 wherein said cross-linking agent is 3,4-dihydroxy-1,5-hexadiene.
Claim 10
Dependent Claim
18 words
A controlled release ophthalmic treatment composition as recited in claim 7 wherein said cross-linking agent is divinyl benzene.
Claim 11
Dependent Claim
17 words
A controlled release ophthalmic treatment composition as recited in claim 7 wherein said cross-linking agent is 1,5-dimethyl-1,5-hexadiene.
Claim 12
Dependent Claim
24 words
A controlled release ophthalmic treatment composition as recited in any one of claims 1-10, inclusive, wherein said ophthalmic treating agent constitutes an anti-inflammatory agent.
Claim 13
Dependent Claim
17 words
A controlled release ophthalmic treatment composition as recited in claim 11 wherein said anti-inflammatory agent is fluorometholone.
Claim 14
Independent Claim
145 words
A method of controlled release ophthalmic treatment comprising the steps of: (A) providing a controlled release ophthalmic treatment composition comprising a bioadhesive and an effective amount of ophthalmic treating agent, said bioadhesive comprising a water-swellable, but water-insoluble , particulate cross-linked carboxyl-functional polymer derived from monomers selected from the group consisting of acrylic acid, methacrylic acid, fumaric acid, maleic acid, maleic anhydride, itaconic acid, crotonic acid, and mixtures thereof having particles sized so that visual impairment is minimized when said composition is contacted with a mucous membrane of the eye, said polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) a cross-linking agent substantially free from polyalkenyl polyether said agent selected from the group consisting of divinyl benzene, N,N-dialkylacrylamide, 3,4-dihydroxy-1,5-hexadiene and 2,5-dimethyl-1,5-hexadiene, said agent being from about 0.05 to 2.0 weight percent.
Claim 15
Independent Claim
145 words
A method of controlled release ophthalmic treatment comprising the steps of: (A) providing a controlled release ophthalmic treatment composition comprising a bioadhesive and an effective amount of ophthalmic treating agent, said bioadhesive comprising a water-swellable, but water-insoluble , particulate cross-linked carboxyl-functional polymer derived from monomers selected from the group consisting of acrylic acid, methacrylic acid, fumaric acid, maleic acid, maleic anhydride, itaconic acid, crotonic acid, and mixtures thereof having particles sized so that visual impairment is minimized when said composition is contacted with a mucous membrane of the eye, said polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) a cross-linking agent substantially free from polyalkenyl polyether said agent selected from the group consisting of divinyl benzene, N,N-dialkylacrylamide, 3,4-dihydroxy-1,5-hexadiene and 2,5-dimethyl-1,5-hexadiene, said agent being from about 0.05 to 2.0 weight percent.
Claim 16
Dependent Claim
19 words
A method as recited in claim 13 wherein said bioadhesive and said treating agent are intimately admixed substantially uniformly.
Claim 17
Dependent Claim
24 words
A method as recited in claim 13 wherein at least about 90 percent of said polymer repeating units contain at least one carboxyl functionality.
Claim 18
Dependent Claim
23 words
A method as recited in claim 13 wherein said polymer contains about 0.01 to about 2 percent by weight of polymerized cross-linking agent.
Claim 19
Dependent Claim
17 words
A method as recited in claim 13 wherein said carboxyl functionality is provided by polymerized acrylic acid.
Claim 20
Dependent Claim
13 words
A method as recited in claim 13 wherein said anti-inflammatory agent is fluorometholone.
Claim 21
Dependent Claim
13 words
A method as recited in claim 18 wherein said anti-inflammatory agent is fluorometholone.
References Cited (Backward Citations)
US3202577A
Cited
US3630200A
Cited
US3641237A
Cited
US3981303A
Cited
US3962414A
Cited
US3935303A
Cited
US3811444A
Cited
US3946106A
Cited
US4180646A
Cited
US4357259A
Cited
US4186184A
Cited
US4304765A
Cited
US4483846A
Cited
US4983392A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-07-05 | 1997-01-04 | 1997-07-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-07-05 | 2001-01-04 | 2001-07-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-07-05 | 2005-01-04 | 2005-07-06 | $7700.00 | Window Closed / Lapsed |